Combined analysis of CSF Tau, A 42, A 142 and A 1 40 ox in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Bibl, Mirko ^a   Esselmann, Hermann ^a   Lewczuk, Piotr ^b   Trenkwalder, Claudia ^c   Otto, Markus ^d   Kornhuber, Johannes ^b   Wiltfang, Jens ^a   Mollenhauer, Brit ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 77957869895     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/761571     Document Type: Article

References (30)

1. Dubois B., Feldman H. H., Jacova C., DeKosky S. T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P. J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria The Lancet Neurology 2007 6 8 734 746
2. Otto M., Lewczuk P., Wiltfang J., Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases Methods 2008 44 4 289 298
3. Bibl M., Mollenhauer B., Lewczuk P., Esselmann H., Wolf S., Trenkwalder C., Otto M., Stiens G., Rther E., Kornhuber J., Wiltfang J., Validation of amyloid- peptides in CSF diagnosis of neurodegenerative dementias Molecular Psychiatry 2007 12 7 671 680
4. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Klafki H.-W., Sparbier K., Smirnov A., Cepek L., Trenkwalder C., Rther E., Kornhuber J., Otto M., Wiltfang J., CSF amyloid- -peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain 2006 129 5 1177 1187
5. World Medical Organisation, Declaration of Helsinki British Medical Journal 1996 313 1448 1449
6. McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 1984 34 7 939 944
7. McKeith I. G., Dickson D. W., Lowe J., Emre M., O'Brien J. T., Feldman H., Cummings J., Duda J. E., Lippa C., Perry E. K., Aarsland D., Arai H., Ballard C. G., Boeve B., Burn D. J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C. G., Gomez-Tortosa E., Halliday G., Hansen L. A., Hardy J., Iwatsubo T., Kalaria R. N., Kaufer D., Kenny R. A., Korczyn A., Kosaka K., Lee V. M. Y., Lees A., Litvan I., Londos E., Lopez O. L., Minoshima S., Mizuno Y., Molina J. A., Mukaetova-Ladinska E. B., Pasquier F., Perry R. H., Schulz J. B., Trojanowski J. Q., Yamada M., Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium Neurology 2005 65 12 1863 1872
8. Gibb W. R. G., Lees A. J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease Journal of Neurology Neurosurgery and Psychiatry 1988 51 6 745 752
9. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., Bancher C., Cras P., Wiltfang J., Mehta P. D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H., Improved discrimination of AD patients using -amyloid(1-42) and tau levels in CSF Neurology 1999 52 8 1555 1562
10. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H.-W., Maler M., Dyrks T., Bienert M., Beyermann M., Rther E., Kornhuber J., Highly conserved and disease-specific patterns of carboxyterminally truncated A peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation Journal of Neurochemistry 2002 81 3 481 496
11. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Rther E., Kornhuber J., Wiltfang J., Cerebrospinal fluid amyloid peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid peptides Electrophoresis 2004 25 17 2912 2918
12. Youden W. J., Index for rating diagnostic tests Cancer 1950 3 1 32 35
13. Blennow K., Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 2004 1 2 213 225
14. Kanemaru K., Kameda N., Yamanouchi H., Decreased CSF amyloid 42 and normal tau levels in dementia with Lewy bodies Neurology 2000 54 9 1875 1876
15. Gmez-Tortosa E., Gonzalo I., Fanjul S., Sainz M. J., Cantarero S., Cemilln C., Garca Ybenes J., Del Ser T., Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease Archives of Neurology 2003 60 9 1218 1222 (Pubitemid 37099626)
16. Mollenhauer B., Cepek L., Bibl M., Wiltfang J., Schulz-Schaeffer W. J., Ciesielczyk B., Neumann M., Steinacker P., Kretzschmar H. A., Poser S., Trenkwalder C., Otto M., Tau protein, A 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies Dementia and Geriatric Cognitive Disorders 2005 19 2-3 164 170 (Pubitemid 40868045)
17. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., Rther E., Kornhuber J., Otto M., Wiltfang J., CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies Journal of Neural Transmission 2006 113 11 1771 1778
18. Jansen S. E., Vermes I., de Vos R. A. I., Cerebrospinal-fluid protein and aspartate aminotransferase in Parkinson's disease The Lancet 1998 351 9109 1105 1106
19. Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Steinacker P., Brechlin P., Schindehuette J., Poser S., Wiltfang J., Otto M., Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia Dementia and Geriatric Cognitive Disorders 2006 22 3 200 208
20. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neuroscience Letters 2001 297 3 187 190
21. Bibl M., Mollenhauer B., Esselmann H., Schneider M., Lewczuk P., Welge V., Gross M., Falkai P., Kornhuber J., Wiltfang J., Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review Dementia and Geriatric Cognitive Disorders 2008 25 3 256 265
22. Davies P., Resnick J., Resnick B., Gilman S., Growdon J. H., Khachaturian Z. S., Radebaugh T. S., Roses A. D., Selkoe D. J., Trojanowski J. Q., Blass J. P., Gibson G. E., Sheu K.-F. R., Blennow K., Delacourte A., Frisoni G. B., Jefferies W. A., McRae A., Wisniewski H. M., Mehta P. D., Pirttla T., Parshad R., Scinto L. F. M., Scheltens P., Riekkinen P. J., Soininen H. S., Swanwick G. R. J., Wahlund L.-O., Arnold S. E., Winblad B., Ihara Y., Yamazaki T., Arai H., Clark C. M., Ewbank D. C., Takase S., Higuchi S., Mirua M., Seki H., Higuchi M., Matsui T., Lee V.M.-Y., Sasaki H., Foster N. L., Galasko D., Hock C., Hyman B. T., St. George-Hyslop P. H., Iwatsubo T., Kennard M., Klunk W. E., Lannfelt L., Litvan I., Mayeux R., Robles A., Fabian V. A., Jones T. M., Wilton S. D., Dench J. E., Davis M. R., Lim L., Kakulas B. A., Kennard M. L., Feldman H., Yamada T., Sweet R. A., Zubenko G. S., Consensus report of the working group on: molecular and biochemical markers of Alzheimer's disease Neurobiology of Aging 1998 19 2 109 116
23. Lewczuk P., Wiltfang J., Neurochemical dementia diagnostics: state of the art and research perspectives Proteomics 2008 8 6 1292 1301
24. Shoji M., Kanai M., Cerebrospinal fluid A 40 and A 42: natural course and clinical usefulness Journal of Alzheimer's Disease 2001 3 3 313 321
25. Lewczuk P., Beck G., Esselmann H., Bruckmoser R., Zimmermann R., Fiszer M., Bibl M., Maler J. M., Kornhuber J., Wiltfang J., Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid peptides Clinical Chemistry 2006 52 2 332 334
26. Wiltfang J., Esselmann H., Bibl M., Hll M., Hampel H., Kessler H., Frlich L., Schrder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J. M., Zimmermann R., Bruckmoser R., Kornhuber J., Lewczuk P., Amyloid peptide ratio 42/40 but not A 42 correlates with phospho-Tau in patients with low- and high-CSF A 40 load Journal of Neurochemistry 2007 101 4 1053 1059
27. Mollenhauer B., Esselmann H., Trenkwalder C., CSF amyloid- peptides in neuropathologically diagnosed dementias with Lewy bodies and Alzheimer's type Brain 2006 129 5 1177 1187
28. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T. F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H. A., McLean P. J., Trenkwalder C., Sarracino D. A., VonSattel J.-P., Locascio J. J., El-Agnaf O. M. A., Schlossmacher M. G., Direct quantification of CSF -synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Experimental Neurology 2008 213 2 315 325
29. Jesse S., Steinacker P., Lehnert S., Gillardon F., Hengerer B., Otto M., Neurochemical approaches in the laboratory diagnosis of parkinson and parkinson dementia syndromes: a review CNS Neuroscience and Therapeutics 2009 15 2 157 182
30. Bibl M., Wiltfang J., Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics Expert Review of Proteomics 2008 5 2 153 156